Article
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2020
Ryan Meagan B, Fece de la Cruz Ferran, Phat Sarah, Myers David T, Wong Edmond, Shahzade Heather A, Hong Catriona B, Corcoran Ryan B
Abstract excerpt
PURPOSE: Although KRAS represents the most commonly mutated oncogene, it has long been considered an "undruggable" target. Novel covalent inhibitors selective for the KRASG12C mutation offer the unprecedented opportunity to target KRAS directly. However, prior efforts to target the RAS-MAPK pathway have been hampered by adaptive feedback, which drives pathway reactivation and resistance. EXPERIMENTAL DESIGN: A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.